<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499315</url>
  </required_header>
  <id_info>
    <org_study_id>20110247</org_study_id>
    <nct_id>NCT02499315</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 357 in Female Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out if AMG 357 is safe and tolerated by women with&#xD;
      Rhematoid Arthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study has stopped due to a decision by Amgen to terminate the program&#xD;
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects reporting of treatment-emergent adverse events or clinically significant changes in physical examinations, vital signs, laboratory safety tests, and ECGs</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AMG 357 pharmacokinetic profile (eg, plasma concentration, maximum observed concentration [Cmax], time at Cmax [Tmax], and area under the concentration-time curve [AUC])</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>AMG 357</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 357</intervention_name>
    <description>Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.</description>
    <arm_group_label>AMG 357</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject provided informed consent.&#xD;
&#xD;
          -  Rheumatoid arthritis present for ≥ 3 months.&#xD;
&#xD;
          -  Global functional class I, II, or III.&#xD;
&#xD;
          -  History of or positive for, Rheumatoid Arthritis&#xD;
&#xD;
          -  Taking methotrexate consecutively for ≥ 12 weeks and on a stable dose at 10-25 mg&#xD;
             weekly.&#xD;
&#xD;
          -  Subjects currently taking NSAIDs or oral corticosteroids.&#xD;
&#xD;
          -  Normal ECG values&#xD;
&#xD;
          -  Immunizations up to date.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive Hepatitis B, Hepatitis C, Positive HIV&#xD;
&#xD;
          -  Sensitivity to any of the products or components to be administered.&#xD;
&#xD;
          -  Malignancy within 3 years&#xD;
&#xD;
          -  Presence of recurrent or chronic infections&#xD;
&#xD;
          -  Evidence of infections within the 30 days prior to randomization&#xD;
&#xD;
          -  Presence of a serious infection&#xD;
&#xD;
          -  Prosthetic joint infection within 3 years or native joint infection within 1 year&#xD;
&#xD;
          -  History of exposure to tuberculosis without a history of prophylactic treatment&#xD;
&#xD;
          -  Class IV RA.&#xD;
&#xD;
          -  Felty's syndrome&#xD;
&#xD;
          -  Chronic pelvic pain or hemorrhagic ovarian cyst within 3 years&#xD;
&#xD;
          -  Any bleeding disorder that is clinically significant&#xD;
&#xD;
          -  Low white blood cell or neutrophil count&#xD;
&#xD;
          -  Elevated serum creatinine clearance&#xD;
&#xD;
          -  Low hemoglobin and platelet count&#xD;
&#xD;
          -  Received live vaccines within 3 months of first dose&#xD;
&#xD;
          -  Alcohol and/or substance abuse within past 12 months&#xD;
&#xD;
          -  Blood donation within 60 days&#xD;
&#xD;
          -  Positive urine screen for drugs of abuse&#xD;
&#xD;
          -  Any prior use of rituximab in the last 6 months (or other B cell depleting agents) and&#xD;
             CD19 levels &lt; lower limits of normal&#xD;
&#xD;
          -  Use of a weekly or bimonthly biologic within 2 weeks or monthly biologic agents within&#xD;
             4 weeks&#xD;
&#xD;
          -  Corticosteroid injections for acute RA flare within 4 weeks&#xD;
&#xD;
          -  Grapefruit juice or grapefruit containing products within 7 days of first dose.&#xD;
&#xD;
          -  All herbal medicines, vitamins, and supplements within the 30 days&#xD;
&#xD;
          -  The use of any experimental/investigational biologic DMARD unless off agent for 3&#xD;
             months; or off for 6 months for B cell depleting agents&#xD;
&#xD;
          -  Known GI disease or GI procedures&#xD;
&#xD;
          -  Women of reproductive potential who are unwilling to practice birth control&#xD;
&#xD;
          -  Women who are pregnant/lactating/breastfeeding&#xD;
&#xD;
          -  Subject with IgG levels &lt; lower limit of normal at screening&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>April 10, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

